This page is provided for research and educational purposes only and does not provide medical advice, diagnosis, treatment recommendations, dosing instructions, or instructions for human use. Research findings should be interpreted within the population, model, formulation, route, outcomes, and study design reported by each cited source.
Tesamorelin (10 mg Vial)
This information is for research and educational use only.
Quick Reference
What is Tesamorelin?
Research overview based on the cited scientific literature.
Goal: Reduce visceral adipose tissue and improve lipid profiles through sustained GH/IGF-1 elevation[3][4].
Storage: Lyophilized refrigerated; reconstituted refrigerated up to 7 days; avoid freeze-thaw.
Storage Instructions
Proper storage preserves peptide quality and efficacy.
Lyophilized: Store at 2–8 °C (35.6–46.4 °F); newer formulations (Egrifta SV) stable at 20–25 °C (68–77 °F) before reconstitution[1].
Reconstituted (with bacteriostatic water): Refrigerate at 2–8 °C (35.6–46.4 °F); use within 7 days[1].
Reconstituted (with sterile water): Use immediately; discard any unused portion[1].
Do not freeze reconstituted solution; avoid repeated freeze-thaw cycles.
How is Tesamorelin studied?
Tesamorelin mimics natural human GHRH by binding to pituitary GHRH receptors, triggering pulsatile growth hormone secretion and consequent IGF-1 elevation[2]. This cascade promotes lipolysis (fat breakdown), protein synthesis, and favorable metabolic shifts. In HIV-associated lipodystrophy, daily tesamorelin significantly reduces visceral adipose tissue and improves lipid profiles over 6–12 months[3][4]. Research also explores tesamorelin’s potential to reduce liver fat in NAFLD patients and enhance cognitive function in older adults by restoring age-related GH/IGF-1 declines[4].
What does the research report about Tesamorelin?
Observations from clinical trials and FDA-approved use.
Potential Benefits:
Significant reduction in visceral adipose tissue (measurable after 3–6 months)[3].
Improved lipid profiles and potential liver fat reduction in NAFLD[4].
Enhanced cognitive function in older adults (research ongoing)[4].
Well-tolerated with maintained benefits during continuous use up to 52 weeks[3].
Common Side Effects:
Injection-site reactions: Mild redness, itching, pain, or bruising at injection area[9].
Musculoskeletal symptoms: Joint pain (arthralgia), muscle aches, peripheral edema (mild swelling)[9].
Carpal tunnel symptoms: Occasional tingling or numbness in extremities (dose-dependent, reversible).
Metabolic monitoring: IGF-1 elevation requires monitoring; small increases in HbA1c observed in some patients[9].
Contraindications:
Active malignancies (tesamorelin may accelerate growth of latent tumors)[9].
Pregnancy (may harm fetus)[9].
Known hypersensitivity to tesamorelin or mannitol[9].
Important Note
This content is provided for scientific research and educational purposes only. It does not provide medical advice, diagnosis, treatment, dosing, or administration instructions. The compounds discussed may be investigational and are not presented as approved for human use.
What are the limitations of the research on Tesamorelin?
Evidence should be interpreted within the population, experimental model, formulation, route, outcome measures, and study design used in each cited source. Preclinical or early-stage findings do not establish clinical efficacy, safety, or approved human use. Where human evidence is available, results should not be generalized beyond the populations and conditions actually studied.